Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Srikanth Bellary is active.

Publication


Featured researches published by Srikanth Bellary.


Current Medical Research and Opinion | 2010

Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study - effect of ethnicity on risk

Srikanth Bellary; J. Paul O'Hare; Neil T. Raymond; S. Mughal; Wasim Hanif; Alan Jones; S. Kumar; Anthony H. Barnett

Abstract Background/Aim: People of south Asian origin have an excessive risk of morbidity and mortality from cardiovascular disease. We examined the effect of ethnicity on known risk factors and analysed the risk of cardiovascular events and mortality in UK south Asian and white Europeans patients with type 2 diabetes over a 2 year period. Methods: A total of 1486 south Asian (SA) and 492 white European (WE) subjects with type 2 diabetes were recruited from 25 general practices in Coventry and Birmingham, UK. Baseline data included clinical history, anthropometry and measurements of traditional risk factors – blood pressure, total cholesterol, HbA1c. Multiple linear regression models were used to examine ethnicity differences in individual risk factors. Ten-year cardiovascular risk was estimated using the Framingham and UKPDS equations. All subjects were followed up for 2 years. Cardiovascular events (CVD) and mortality between the two groups were compared. Trial registration number: ISRCTN 38297969. Findings: Significant differences were noted in risk profiles between both groups. After adjustment for clustering and confounding a significant ethnicity effect remained only for higher HbA1c (0.50 [0.22 to 0.77]; P = 0.0004) and lower HDL (−0.09 [−0.17 to −0.01]; P = 0.0266). Baseline CVD history was predictive of CVD events during follow-up for SA (P < 0.0001) but not WE (P = 0.189). Mean age at death was 66.8 (11.8) for SA vs. 74.2 (12.1) for WE, a difference of 7.4 years (95% CI 1.0 to 13.7 years), P = 0.023. The adjusted odds ratio of CVD event or death from CVD was greater but not significantly so in SA than in WE (OR 1.4 [0.9 to 2.2]). Limitations: Fewer events in both groups and short period of follow-up are key limitations. Longer follow-up is required to see if the observed differences between the ethnic groups persist. Conclusion: South Asian patients with type 2 diabetes in the UK have a higher cardiovascular risk and present with cardiovascular events at a significantly younger age than white Europeans. Enhanced and ethnicity specific targets and effective treatments are needed if these inequalities are to be reduced.


Diabetes and Vascular Disease Research | 2006

Inhaled insulin (Exubera ® ): combining efficacy and convenience

Srikanth Bellary; Anthony H. Barnett

The pulmonary route, due to its rich vascularity, large surface area and immunotolerant characteristics, may be an ideal target for drug delivery. Although the inhaled route has been used to deliver drugs used in the management of respiratory disorders, success with peptide delivery has been limited by poor bioavailability. Recent advances in technology have overcome these barriers and have enabled new delivery devices to be developed. Insulin is the first peptide to be delivered successfully by this route and the first of the inhaled insulin delivery devices (Exubera®) has now been approved for clinical use. In clinical trials it has been shown to be effective, apparently safe and a preferred alternative to subcutaneously injected meal-time insulin. This new technology offers great convenience to patients needing insulin treatment. While it will considerably reduce the number of injections needed by people with type 1 and type 2 diabetes, it should also encourage more patients to start insulin treatment earlier. The potential benefits from improved adherence and better glycaemic control with this insulin are also significant.


The British Journal of Diabetes & Vascular Disease | 2006

Review: Inhaled insulin: overcoming barriers to insulin therapy?

Srikanth Bellary; Anthony H. Barnett

Inhaled insulin is a new route of insulin delivery that can be used in the treatment of type 1 and type 2 diabetes. It offers an alternative and additional means of insulin administration, and has been received with particular satisfaction by patients who dislike injections. Trials indicate that inhaled insulin can be used effectively for pre-meal bolus intensification of treatment. Pre-meal inhaled insulin with Exubera® has shown faster absorption and similar duration of action to regular subcutaneous insulin with an overall similar glucodynamic effect. Although bioavailability is lower, mainly due to losses in the upper airways, this is compensated for by dose. The commonest side effect reported with inhaled insulin, as with subcutaneous insulin, was hypoglycaemia, almost a quarter of patients noted a cough which settled with continued treatment. Increased antibody titres and changes in lung function return to normal on discontinuation of inhaled insulin. Quality of life scores indicate patient preference for inhaled versus injected insulin, thus increased choice may improve adherence to treatment regimens. However, true cost:benefit analyses have to be undertaken as do studies in children, smokers and people with respiratory conditions, e.g. asthma. Br J Diabetes Vasc Dis 2006;6:103‐08


Archive | 2010

Replication of European GWAS-derived type 2 diabetes susceptibility SNPs in Pakistani populations

Simon D. Rees; Srikanth Bellary; M. Z. I. Hydrie; J. Paul O'Hare; S. Kumar; A. S. Shera; Abdul Basit; Anthony H. Barnett; M. A. Kelly

Background and aims: The association between type 2 diabetes and different forms of cognitive impairment is well established. The mechanism behind the association is however still unrevealed. We ha ...


Archive | 2006

Inhaled insulin: overcoming barriers to insulin therapy?

Srikanth Bellary; Anthony H. Barnett


Practical Diabetes International | 2007

Microvascular and cardiovascular disease in South Asians: the emerging challenge

M Varma Chittari; K Bush; Srikanth Bellary; S. Kumar; Anthony H. Barnett; Jp O' Hare


Practical Diabetes International | 2006

Novel metabolic drugs for the management of type 2 diabetes

Anthony H. Barnett; Srikanth Bellary


Free Radical Biology and Medicine | 2016

Odd-Chain Fatty Acids Predict Insulin Sensitivity in People with T2DM and Protect HepG2 Cells from Palmitate-Induced Insulin Resistance Via PPARα

Ogwu John Ikwuobe; Karan S. Rana; James Brown; Chathyan Pararasa; Kiran Shabir; Srikanth Bellary; Clifford J. Bailey; Helen R. Griffiths


Archive | 2009

Central obesity and cardiovascular risk factors in south Asians and white Europeans with type 2 diabetes. A report from the United Kingdom Asian Diabetes Study (UKADS)

Abd A. Tahrani; Srikanth Bellary; J. Paul O'Hare; S. Mughal; Neil T. Raymond; K. Johal; S. Kumar; Anthony H. Barnett; Asad Rahim


Archive | 2008

Cardiovascular risk targets in type 2 diabetes should be lower for patients of south Asian ethnicity : the United Kingdom Asian Diabetes Study (UKADS)

Srikanth Bellary; Neil T. Raymond; J. Paul O'Hare; S. Mughal; K. Johal; S. Kumar; Anthony H. Barnett

Collaboration


Dive into the Srikanth Bellary's collaboration.

Top Co-Authors

Avatar

Anthony H. Barnett

Heart of England NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

S. Kumar

University of Warwick

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S. Mughal

Heart of England NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. C. Britten

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar

A. N. Dixon

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar

Abd A. Tahrani

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar

Alan Jones

Heart of England NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Asad Rahim

University of Birmingham

View shared research outputs
Researchain Logo
Decentralizing Knowledge